{"nctId":"NCT03433040","briefTitle":"17OHP-C Dosing Among Obese Pregnant Women","startDateStruct":{"date":"2017-08-23","type":"ACTUAL"},"conditions":["Premature Birth","Absorption; Chemicals"],"count":44,"armGroups":[{"label":"non obese","type":"OTHER","interventionNames":["Drug: 17-Hydroxyprogesterone Capronate"]},{"label":"obese - control","type":"OTHER","interventionNames":["Drug: 17-Hydroxyprogesterone Capronate"]},{"label":"obese","type":"EXPERIMENTAL","interventionNames":["Drug: 17-Hydroxyprogesterone Capronate"]}],"interventions":[{"name":"17-Hydroxyprogesterone Capronate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* \\- Pregnant women, with a singleton gestation\n* Ages 18 - 55\n* Able to read and write in English and / or Spanish\n* History of spontaneous PTB\n* Obesity (â‰¥ 30 kg / m2 ) vs non-obese groups (18 - 29.9 kg / m2 ) defined by first documented body mass index at an office visit\n* Gestational age between 12 weeks, 0 days and 24 weeks, 6 days of gestation\n* An ultrasound before 24 + 6 weeks gestation to confirm dating and to rule out major fetal anomalies\n* Willing to have weekly injections at the physician's office\n* The newborn will be enrolled on the mothers consent for chart review only\n\nhttps://register.clinicaltrials.gov/prs/html/definitions.html?popup=true#Eligibility\n\nExclusion Criteria:\n\n* \\- Multifetal gestation\n* Known fetal anomaly\n* Current progesterone treatment\n* Known or suspected breast cancer, other hormone-sensitive cancer, or history of these conditions\n* Current or history of thrombosis or thromboembolic disorder\n* Current anticoagulation\n* Undiagnosed abnormal vaginal bleeding unrelated to pregnancy\n* Cholestatic jaundice of pregnancy\n* Liver tumors, benign or malignant, or active liver disease\n* uncontrolled hypertension (controlled hypertension is eligible)\n* A seizure disorder\n* Current or planned cervical cerclage\n* Plan to deliver elsewhere","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Trough Levels of 17-OHPC in the Three Groups at 20-22 Weeks, 27-29 Weeks and 34-36 Weeks.","description":"Blood levels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"4.5"},{"groupId":"OG001","value":"13.0","spread":"5.1"},{"groupId":"OG002","value":"18.0","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"4.8"},{"groupId":"OG001","value":"8.1","spread":"5.6"},{"groupId":"OG002","value":"17.9","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"12.5"},{"groupId":"OG001","value":"11.1","spread":"6.2"},{"groupId":"OG002","value":"24.6","spread":"7.1"}]}]}]},{"type":"SECONDARY","title":"Gestational Age at Delivery","description":"Gestational age at delivery in weeks . Too few to dichotomize to \\<37, 34 and 32 weeks as previously planned.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":"2.6"},{"groupId":"OG001","value":"38.4","spread":"1.4"},{"groupId":"OG002","value":"32.2","spread":"5.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":[]}}}